Symbols / INM Stock $0.77 +1.22% InMed Pharmaceuticals Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • Canada • NCM
INM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Eric A. Adams B.S. Chem., M.I.B.
Exch · Country NCM · Canada
Market Cap 2.56M
Enterprise Value -4.21M
Income -7.66M
Sales 4.51M
FCF (ttm) -4.31M
Book/sh 3.42
Cash/sh 2.40
Employees 13
Insider 10d —
IPO May 05, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.12
PEG —
P/S 0.57
P/B 0.23
P/C —
EV/EBITDA 0.55
EV/Sales -0.94
Quick Ratio 4.85
Current Ratio 5.94
Debt/Eq 5.55
LT Debt/Eq —
EPS (ttm) -2.88
EPS next Y -6.25
EPS Growth —
Revenue Growth -26.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2022-11-15
ROA -49.77%
ROE -97.20%
ROIC —
Gross Margin 29.73%
Oper. Margin -258.57%
Profit Margin -170.07%
Shs Outstand 3.31M
Shs Float 2.16M
Insider Own 0.12%
Instit Own 9.43%
Short Float 2.90%
Short Ratio 0.55
Short Interest 95.64K
52W High 7.98
vs 52W High -90.33%
52W Low 0.57
vs 52W Low 34.16%
Beta 0.52
Impl. Vol. —
Rel Volume 0.38
Avg Volume 107.61K
Volume 41.07K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.76
Price $0.77
Change 1.22%
About

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.77
Latest analyst target
3. DCF / Fair value
$-23.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.77
Low
—
High
—
Mean
—
News
RSS: Latest INM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-07-31 MANCINI ALEXANDRA DIANE JANET Unknown — 240 $0.18 $42
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
4.94
+7.50%
4.60
+11.18%
4.14
+279.61%
1.09
Operating Revenue
4.94
+7.50%
4.60
+11.18%
4.14
+279.61%
1.09
Cost Of Revenue
3.24
-7.46%
3.50
+27.97%
2.73
+400.56%
0.55
Reconciled Cost Of Revenue
2.91
-6.35%
3.11
+33.06%
2.34
+964.25%
0.22
Gross Profit
1.71
+55.02%
1.10
-21.53%
1.40
+158.13%
0.54
Research And Development
2.85
-11.30%
3.22
-13.79%
3.73
-48.75%
7.28
Selling General And Administration
6.56
+13.10%
5.80
-0.84%
5.85
-14.85%
6.87
General And Administrative Expense
6.56
+13.10%
5.80
-0.84%
5.85
-14.85%
6.87
Other Gand A
6.56
+13.10%
5.80
-0.84%
5.85
-14.85%
6.87
Total Expenses
12.86
+1.01%
12.73
+1.74%
12.51
-15.90%
14.88
Operating Income
-7.92
+2.66%
-8.13
+2.92%
-8.38
+39.25%
-13.79
EBITDA
-7.26
-2.72%
-7.06
+9.24%
-7.78
+41.39%
-13.28
Normalized EBITDA
-7.23
-3.22%
-7.00
+9.47%
-7.73
+7.65%
-8.38
Reconciled Depreciation
0.53
-11.55%
0.60
+1.43%
0.60
+16.45%
0.51
EBIT
-7.79
-1.59%
-7.67
+8.48%
-8.38
+39.25%
-13.79
Total Unusual Items
-0.03
+54.02%
-0.06
-28.53%
-0.05
+99.02%
-4.90
Total Unusual Items Excluding Goodwill
-0.03
+54.02%
-0.06
-28.53%
-0.05
+99.02%
-4.90
Special Income Charges
—
—
0.00
+100.00%
-3.47
Impairment Of Capital Assets
—
—
0.00
-100.00%
3.47
Net Income
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Pretax Income
-8.16
-6.44%
-7.67
+3.35%
-7.93
+57.34%
-18.60
Net Non Operating Interest Income Expense
-0.22
-140.85%
0.53
+7.20%
0.49
+412.48%
0.10
Interest Expense Non Operating
0.37
0.00
—
0.00
Net Interest Income
-0.22
-140.85%
0.53
+7.20%
0.49
+412.48%
0.10
Interest Expense
0.37
0.00
—
0.00
Interest Income Non Operating
0.16
-70.47%
0.53
+7.20%
0.49
+412.48%
0.10
Interest Income
0.16
-70.47%
0.53
+7.20%
0.49
+412.48%
0.10
Other Income Expense
-0.03
+54.02%
-0.06
-28.53%
-0.05
+99.02%
-4.90
Gain On Sale Of Security
-0.03
+54.02%
-0.06
-28.53%
-0.05
+96.64%
-1.43
Tax Provision
0.00
-100.00%
0.01
-45.80%
0.01
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
-62.50%
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.01
+51.80%
-0.02
0.00
Net Income Including Noncontrolling Interests
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Net Income From Continuing Operation Net Minority Interest
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Net Income From Continuing And Discontinued Operation
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Net Income Continuous Operations
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Normalized Income
-8.13
-6.70%
-7.62
+3.74%
-7.92
+42.18%
-13.70
Net Income Common Stockholders
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Diluted EPS
-8.36
+58.61%
-20.20
+68.92%
-65.00
+90.20%
-663.40
Basic EPS
-8.36
+58.61%
-20.20
+68.92%
-65.00
+90.20%
-663.40
Basic Average Shares
0.98
+156.13%
0.38
+211.26%
0.12
+336.58%
0.03
Diluted Average Shares
0.98
+156.13%
0.38
+211.26%
0.12
+336.58%
0.03
Diluted NI Availto Com Stockholders
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Depreciation Amortization Depletion Income Statement
0.21
-3.08%
0.22
+8.58%
0.20
+8.94%
0.19
Depreciation And Amortization In Income Statement
0.21
-3.08%
0.22
+8.58%
0.20
+8.94%
0.19
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
15.58
+31.78%
11.82
-16.19%
14.11
+10.31%
12.79
Current Assets
12.87
+48.08%
8.69
-23.32%
11.33
+18.07%
9.60
Cash Cash Equivalents And Short Term Investments
11.08
+68.54%
6.57
-26.27%
8.91
+44.29%
6.18
Cash And Cash Equivalents
11.08
+68.54%
6.57
-26.27%
8.91
+44.29%
6.18
Other Short Term Investments
—
—
—
0.04
Receivables
0.47
+31.82%
0.35
+35.50%
0.26
+195.82%
0.09
Accounts Receivable
0.47
+31.82%
0.35
+35.50%
0.26
+195.82%
0.09
Gross Accounts Receivable
0.47
+32.51%
0.35
+7.84%
0.33
—
Allowance For Doubtful Accounts Receivable
-0.00
0.00
+100.00%
-0.07
—
Inventory
0.96
-22.76%
1.24
-23.02%
1.62
-35.11%
2.49
Raw Materials
0.26
-30.69%
0.37
+78.55%
0.21
-28.66%
0.29
Work In Process
0.03
-13.38%
0.03
-94.01%
0.51
-70.19%
1.72
Finished Goods
0.68
-19.58%
0.84
-5.90%
0.89
+88.73%
0.47
Prepaid Assets
—
—
—
0.80
Restricted Cash
0.04
+0.74%
0.04
-3.06%
0.04
-0.85%
0.04
Other Current Assets
0.32
-32.65%
0.48
-4.07%
0.50
-37.53%
0.80
Total Non Current Assets
2.71
-13.42%
3.13
+12.92%
2.77
-13.02%
3.19
Net PPE
0.99
-20.62%
1.25
+72.79%
0.72
-20.00%
0.90
Gross PPE
2.33
-10.55%
2.61
+58.02%
1.65
+16.05%
1.42
Accumulated Depreciation
-1.34
+1.25%
-1.36
-46.47%
-0.93
-79.16%
-0.52
Properties
—
—
—
0.00
Machinery Furniture Equipment
0.00
-100.00%
0.04
+0.00%
0.04
+0.00%
0.04
Other Properties
2.33
-9.14%
2.56
+59.48%
1.61
+16.52%
1.38
Leases
—
—
—
0.04
Goodwill And Other Intangible Assets
1.62
-9.12%
1.78
-8.38%
1.95
-7.71%
2.11
Other Intangible Assets
1.62
-9.12%
1.78
-8.38%
1.95
-7.71%
2.11
Other Non Current Assets
0.10
+0.00%
0.10
-4.68%
0.10
-40.61%
0.18
Total Liabilities Net Minority Interest
2.15
-18.00%
2.62
+29.76%
2.02
-45.63%
3.71
Current Liabilities
1.84
-6.70%
1.97
-1.44%
2.00
-39.73%
3.32
Payables And Accrued Expenses
0.91
-21.60%
1.17
+9.31%
1.07
-61.59%
2.78
Payables
0.37
-40.89%
0.63
+15.07%
0.54
-67.34%
1.67
Accounts Payable
0.37
-40.89%
0.63
+15.07%
0.54
-53.33%
1.17
Other Payable
—
—
—
0.50
Current Accrued Expenses
0.54
+0.78%
0.54
+3.31%
0.52
-52.95%
1.11
Pensionand Other Post Retirement Benefit Plans Current
0.49
+0.44%
0.49
-9.96%
0.54
+289.81%
0.14
Current Debt And Capital Lease Obligation
0.44
+37.04%
0.32
-15.41%
0.38
-7.07%
0.40
Current Capital Lease Obligation
0.44
+37.04%
0.32
-15.41%
0.38
-7.07%
0.40
Current Deferred Liabilities
—
0.00
-100.00%
0.02
0.00
Total Non Current Liabilities Net Minority Interest
0.31
-52.59%
0.64
+3931.92%
0.02
-95.89%
0.39
Long Term Debt And Capital Lease Obligation
0.31
-52.59%
0.64
+3931.92%
0.02
-95.89%
0.39
Long Term Capital Lease Obligation
0.31
-52.59%
0.64
+3931.92%
0.02
-95.89%
0.39
Stockholders Equity
13.43
+45.93%
9.21
-23.85%
12.09
+33.17%
9.08
Common Stock Equity
13.43
+45.93%
9.21
-23.85%
12.09
+33.17%
9.08
Capital Stock
91.22
+10.19%
82.78
+6.65%
77.62
+9.76%
70.72
Common Stock
91.22
+10.19%
82.78
+6.65%
77.62
+9.76%
70.72
Share Issued
2.00
+348.97%
0.45
+167.98%
0.17
+411.51%
0.03
Ordinary Shares Number
2.00
+348.97%
0.45
+167.98%
0.17
+411.51%
0.03
Additional Paid In Capital
39.32
+11.18%
35.37
-1.04%
35.74
+12.80%
31.68
Retained Earnings
-117.24
-7.48%
-109.08
-7.57%
-101.40
-8.50%
-93.45
Gains Losses Not Affecting Retained Earnings
0.13
+0.00%
0.13
+0.00%
0.13
+0.00%
0.13
Other Equity Adjustments
0.13
+0.00%
0.13
+0.00%
0.13
+0.00%
0.13
Total Equity Gross Minority Interest
13.43
+45.93%
9.21
-23.85%
12.09
+33.17%
9.08
Total Capitalization
13.43
+45.93%
9.21
-23.85%
12.09
+33.17%
9.08
Working Capital
11.03
+64.15%
6.72
-28.01%
9.33
+48.63%
6.28
Invested Capital
13.43
+45.93%
9.21
-23.85%
12.09
+33.17%
9.08
Total Debt
0.74
-23.00%
0.96
+145.76%
0.39
-50.65%
0.79
Capital Lease Obligations
0.74
-23.00%
0.96
+145.76%
0.39
-50.65%
0.79
Net Tangible Assets
11.81
+59.15%
7.42
-26.82%
10.14
+45.54%
6.97
Tangible Book Value
11.81
+59.15%
7.42
-26.82%
10.14
+45.54%
6.97
Foreign Currency Translation Adjustments
—
—
—
0.13
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-7.77
-11.18%
-6.99
+4.08%
-7.28
+53.26%
-15.58
Cash Flow From Continuing Operating Activities
-7.77
-11.18%
-6.99
+4.08%
-7.28
+53.26%
-15.58
Net Income From Continuing Operations
-8.16
-6.34%
-7.68
+3.42%
-7.95
+57.27%
-18.60
Depreciation Amortization Depletion
0.53
-11.55%
0.60
+1.43%
0.60
+16.45%
0.51
Depreciation
0.37
-14.00%
0.43
+9.88%
0.39
+11.68%
0.35
Amortization Cash Flow
0.16
-5.37%
0.17
-15.03%
0.20
+27.02%
0.16
Depreciation And Amortization
0.53
-11.55%
0.60
+1.43%
0.60
+16.45%
0.51
Amortization Of Intangibles
0.16
-5.37%
0.17
-15.03%
0.20
+27.02%
0.16
Other Non Cash Items
-0.00
+97.20%
-0.00
-55.67%
-0.00
-100.06%
1.39
Stock Based Compensation
0.12
-13.37%
0.14
-50.49%
0.28
-60.14%
0.70
Provisionand Write Offof Assets
0.00
0.00
-100.00%
0.05
0.00
Asset Impairment Charge
0.00
-100.00%
0.31
-1.01%
0.31
-91.10%
3.47
Operating Gains Losses
0.08
+519.21%
0.01
+936.52%
0.00
-90.99%
0.01
Gain Loss On Investment Securities
—
—
—
—
Net Foreign Currency Exchange Gain Loss
0.08
+519.21%
0.01
+936.52%
0.00
-33.16%
0.00
Change In Working Capital
-0.34
+8.71%
-0.37
+34.73%
-0.57
+81.59%
-3.07
Change In Receivables
-0.11
-24.07%
-0.09
+57.82%
-0.22
-447.76%
-0.04
Changes In Account Receivables
-0.11
-24.07%
-0.09
+57.82%
-0.22
-447.76%
-0.04
Change In Inventory
0.28
+327.59%
0.07
-88.29%
0.57
+128.23%
-2.00
Change In Prepaid Assets
0.17
+757.72%
0.02
-93.22%
0.30
+56.92%
0.19
Change In Payables And Accrued Expense
-0.25
-651.50%
0.05
+105.61%
-0.81
+0.62%
-0.81
Change In Other Working Capital
—
-0.02
-200.00%
0.02
+414.49%
-0.01
Change In Other Current Assets
0.00
-100.00%
0.00
-10.88%
0.01
+108.96%
-0.06
Change In Other Current Liabilities
-0.43
-8.17%
-0.40
+6.83%
-0.43
-24.78%
-0.34
Investing Cash Flow
0.00
+100.00%
-0.01
+98.60%
-0.66
+1.66%
-0.67
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.01
+98.60%
-0.66
+1.66%
-0.67
Net PPE Purchase And Sale
0.00
+100.00%
-0.01
+94.26%
-0.16
-313.74%
-0.04
Purchase Of PPE
0.00
+100.00%
-0.01
+94.26%
-0.16
-313.74%
-0.04
Sale Of PPE
—
—
—
—
Capital Expenditure
—
-0.01
+94.26%
-0.16
-313.74%
-0.04
Net Investment Purchase And Sale
0.00
0.00
0.00
0.00
Purchase Of Investment
-0.04
-0.45%
-0.04
+0.44%
-0.04
0.00
Sale Of Investment
0.04
+0.45%
0.04
-0.44%
0.04
0.00
Net Business Purchase And Sale
—
0.00
+100.00%
-0.50
-139.36%
-0.21
Purchase Of Business
—
0.00
+100.00%
-0.50
-66.41%
-0.30
Net Other Investing Changes
—
—
—
-0.42
Financing Cash Flow
12.27
+163.66%
4.65
-56.42%
10.68
-29.13%
15.07
Cash Flow From Continuing Financing Activities
12.27
+163.66%
4.65
-56.42%
10.68
-29.13%
15.07
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.29
Repayment Of Debt
—
—
0.00
+100.00%
-0.29
Long Term Debt Payments
—
—
0.00
+100.00%
-0.29
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.29
Net Common Stock Issuance
8.13
+55.87%
5.22
-51.16%
10.68
-37.71%
17.15
Proceeds From Stock Option Exercised
5.02
+2871266.29%
0.00
-72.91%
0.00
—
Net Other Financing Charges
-0.88
-57.25%
-0.56
+57.41%
-1.32
+26.05%
-1.78
Changes In Cash
4.50
+292.42%
-2.34
-185.57%
2.74
+330.61%
-1.19
Effect Of Exchange Rate Changes
—
—
—
0.00
Beginning Cash Position
6.57
-26.27%
8.91
+44.29%
6.18
-16.11%
7.36
End Cash Position
11.08
+68.54%
6.57
-26.27%
8.91
+44.29%
6.18
Free Cash Flow
-7.77
-11.03%
-7.00
+6.04%
-7.45
+52.35%
-15.62
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
-100.00%
0.01
-45.80%
0.01
0.00
Common Stock Issuance
8.13
+55.87%
5.22
-51.16%
10.68
-37.71%
17.15
Interest Received CFO
—
—
—
—
Issuance Of Capital Stock
8.13
+55.87%
5.22
-51.16%
10.68
-37.71%
17.15
Sale Of Business
—
—
0.00
-100.00%
0.09
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category